Back to search
FDAFDA · Food and drugs·Recall number Z-0489-2025

cobas HCYS, Homocysteine Enzymatic Assay, Material Number REF 06542921190, for use on cobas c 701/702, in vitro test for total L-homocysteine

Published November 27, 2024 · Recall initiated: October 17, 2024

Summary

FDA records medical device Class II recall Z-0489-2025, published November 27, 2024 and initiated October 17, 2024. Recalling firm: Roche Diagnostics Operations, Inc.; Status: Ongoing; Reported quantity: 458 units; Lot: UDI/DI 04015630929979, Lot Number 747029, exp. 30-SEPT-2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Abnormal calibration signals and control recovery issues on the Homocysteine Enzymatic (HCYS) Assay can produce erroneous patient results (positive or negative bias)

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Roche Diagnostics Operations, Inc.
Distributor
US: NJ, TX, NY, FL, IN, TX, OK, SC, IA,
Lot
UDI/DI 04015630929979, Lot Number 747029, exp. 30-SEPT-2024
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was cobas HCYS, Homocysteine Enzymatic Assay, Material Number REF 06542921190, for use on cobas c 701/702, in vitro test for total L-homocysteine recalled?

Yes. FDA published recall Z-0489-2025 on November 27, 2024. Reported hazard: Abnormal calibration signals and control recovery issues on the Homocysteine Enzymatic (HCYS) Assay can produce erroneous patient results (positive or negative bias)

What should I do if I have this product?

Voluntary: Firm initiated · Letter